# CosmosID

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cosmosid

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.cosmosid.com
- Total disclosed funding: $6M
- Latest round: Series B (Jan 26, 2016)
- Investors on record: 1

## About

CosmosID delivers advanced microbiome bioinformatics and metagenomics services, aiding researchers with comprehensive insights into microbial communities through specialized sequencing techniques.Founded in 2008 and headquartered in Rockville, US, CosmosID provides microbiome analysis services. The company has executed 2 deals, with the most recent being a Series B round in January 2016, raising USD 6.00 mn from Applied Value Group. CEO Manoj Dadlani leads the company, which has maintained its original business strategy focused on microbiome research without any pivots or changes in operations.CosmosID specializes in delivering advanced microbiome bioinformatics and metagenomics services. Their core offerings include amplicon sequencing, shallow and deep shotgun sequencing, metatranscriptomics, and bacterial isolate sequencing. These services enable researchers and clinicians to achieve detailed insights into microbial communities, facilitating comprehensive taxonomic profiling and functional metagenomic analysis. CosmosID's solutions cater to a diverse clientele comprising academic institutions, healthcare providers, and pharmaceutical companies across various geographical markets, including North America, Europe, and Asia. By providing high-quality sequencing data and exceptional bioinformatics support, CosmosID addresses critical challenges in microbiome research, helping clients to develop therapeutics, publish scientific studies, and diagnose health conditions.CosmosID operates primarily on a B2B model, engaging with clients through customized service agreements and project-based transactions. Their revenue structure is built around delivering tailored sequencing projects that can include both one-time testing and ongoing research collaborations. Clients typically engage CosmosID for specific services such as deep shotgun sequencing or strain-level metagenomics, which can be structured as partnerships that involve multiple phases of research or analysis. Notable offerings include their proprietary metagenomics pipeline and user-friendly software, which facilitate high-resolution data analysis. Transactions are conducted under agreed terms that reflect the complexity and scope of the services rendered, ensuring that clients receive timely and high-quality results for their microbiome studies.In January 2016, CosmosID raised USD 6.00 mn in Series B funding from Applied Value Group, which will support the development of new products and services. The company is focused on expanding its market reach into Europe and Asia by 2024. Plans include launching enhanced metagenomics tools aimed at improving data analysis for clients while entering new geographic territories to broaden their service offerings.

## Funding rounds

- Series B, Jan 26, 2016, $6M — Applied Value Group

## Investors

- Applied Value Group (https://capitalatlas.ai/funds/applied-value-group) — Series B